Anthea M Mitchell
Overview
Explore the profile of Anthea M Mitchell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schrom J, Marquez C, Wang C, Saxena A, Mitchell A, Ribeiro S, et al.
PLoS One
. 2023 Mar;
18(3):e0283576.
PMID: 36961855
COVID-19 oral treatments require initiation within 5 days of symptom onset. Although antigen tests are less sensitive than RT-PCR, rapid results could facilitate entry to treatment. We collected anterior nasal...
2.
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard P, Vazquez S, Liu J, Laurie M, Wang C, Gervais A, et al.
Sci Immunol
. 2022 Jul;
8(90):eabp8966.
PMID: 35857576
Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie...
3.
Acharya C, Schrom J, Mitchell A, Coil D, Marquez C, Rojas S, et al.
Open Forum Infect Dis
. 2022 Apr;
9(5):ofac135.
PMID: 35479304
We found no significant difference in cycle threshold values between vaccinated and unvaccinated persons infected with severe acute respiratory syndrome coronavirus 2 Delta, overall or stratified by symptoms. Given the...
4.
Liu J, Laurie M, Rubio L, Vazquez S, Sunshine S, Mitchell A, et al.
Clin Infect Dis
. 2022 Jan;
75(1):e303-e306.
PMID: 35037050
While SARS-CoV-2 vaccines prevent severe disease effectively, postvaccination "breakthrough" COVID-19 infections and transmission among vaccinated individuals remain ongoing concerns. We present an in-depth characterization of transmission and immunity among vaccinated...
5.
Laurie M, Liu J, Sunshine S, Peng J, Black D, Mitchell A, et al.
medRxiv
. 2022 Jan;
PMID: 34981075
Summary: This study characterizes neutralization of eight different SARS-CoV-2 variants, including Delta and Omicron, with respect to nine different prior exposures, including vaccination, booster, and infections with Delta, Epsilon, and...
6.
Laurie M, Liu J, Sunshine S, Peng J, Black D, Mitchell A, et al.
J Infect Dis
. 2022 Jan;
225(11):1909-1914.
PMID: 34979030
The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of immune responses to different spike protein versions. Here,...
7.
Peng J, Liu J, Mann S, Mitchell A, Laurie M, Sunshine S, et al.
Clin Infect Dis
. 2021 Mar;
74(1):32-39.
PMID: 33788923
Background: Sequencing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral genome from patient samples is an important epidemiological tool for monitoring and responding to the pandemic, including the...
8.
Peng J, Mann S, Mitchell A, Liu J, Laurie M, Sunshine S, et al.
medRxiv
. 2021 Mar;
PMID: 33688689
Background: Sequencing of the SARS-CoV-2 viral genome from patient samples is an important epidemiological tool for monitoring and responding to the pandemic, including the emergence of new mutations in specific...